Onconova Therapeutics, Inc. announced that the first patient has been dosed in the US Phase I clinical trial of ON 123300, the company’s novel multi-kinase inhibitor, for HR+ HER 2– metastatic breast cancer patients who are refractory to, or progressing on, currently approved CDK 4/6 inhibitors.
[Onconova Therapeutics, Inc. (Globe Newswire, Inc.)]
Sorry, but the selected Zotpress account can't be found.
